[Guacetisal: a new molecule with balsamic-antiphlogistic action. Clinical study].
An open clinical trial was run on the therapeutic efficacy of a new balsamic-antiinflammatory molecule, guacetisal (presented as 500 mg Broncaspin capsules). The drug was given for a minimum of 7 days to 45 male and female patients with an average age of 64 yr suffering from variously serious diseases of the airways. The concomitant administration of fluidifying, balsamic, steroid, antipyretic and anti-inflammatory drugs was avoided, whereas various combinations of cardiokinetics, diuretics, theophyllines, and antibiotics were used where required. Clinical assessment of the parameters chosen pointed to the good therapeutic activity of the preparation, which is specifically indicated in inflammatory conditions of the airways, especially chronic forms subject to periodic recrudescence. Its equally good tolerability serves to make guacetisal extremely easy to use, with the results that its employment in non-specialist environments can also be recommended.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D014136:Tracheitis / Q000188:drug therapy
D001241:Aspirin; C023557:guacetisal
Guacetisal: nuova molecola ad azione balsamico-antiflogistica. Studio clinico.